BiotechTube

Org 28611 + morphine sulfate + Placebo

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Analgesia

Conditions

Analgesia

Trial Timeline

Jul 1, 2007 → Aug 1, 2007

NCT ID
NCT00782951

About Org 28611 + morphine sulfate + Placebo

Org 28611 + morphine sulfate + Placebo is a phase 2 stage product being developed by Merck for Analgesia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00782951. Target conditions include Analgesia.

What happened to similar drugs?

5 of 10 similar drugs in Analgesia were approved

Approved (5) Terminated (0) Active (5)
✅Bupivacaine Liposome InjectionJiangsu Hengrui MedicineApproved
✅HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenHeron TherapeuticsApproved
✅Bupivacaine HClHeron TherapeuticsApproved
✅Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionHeron TherapeuticsApproved
✅Bupivacaine Hydrochloride + Bupivacaine Hydrochloride + HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsApproved
🔄Ibuprofen 600 mg Immediate Release/Extended Release CapletPfizerPhase 3
🔄HSK21542 Injection + Tramadol hydrochloride + placeboHaisco Pharmaceutical GroupPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00782951Phase 2Terminated

Competing Products

20 competing products in Analgesia

See all competitors
ProductCompanyStageHype Score
AcetaminophenJohnson & JohnsonPhase 2
42
HRF2105 patch + Loxoprofen patch + placeboJiangsu Hengrui MedicinePhase 2
31
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparationJiangsu Hengrui MedicinePhase 1
29
Bupivacaine Liposome InjectionJiangsu Hengrui MedicineApproved
50
Paracetamol injection + Normal Saline injection + Morhpine PCAJiangsu Hengrui MedicinePhase 2/3
38
Bupivacaine Liposome Injection + Bupivacaine Hydrochloride InjectionJiangsu Hengrui MedicinePhase 2
42
oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + marketed oxycodone hydrochloridePfizerPhase 1
29
Ibuprofen 600 mg Immediate Release/Extended Release CapletPfizerPhase 3
40
HSK21542 Injection + Tramadol hydrochloride + placeboHaisco Pharmaceutical GroupPhase 3
40
Experimental: stage I：HSK21542 0.4 μg/kg + Experimental: stage I：HSK21542 1 μg/kg + Experimental: stage I：HSK21542 0.5μg/kg + Experimental: stage I：HSK21542 1μg/kg + Experimental: stage II：HSK21542 0.5μg/kg + Experimental: stage II：HSK21542 1μg/kg + PlaceboHaisco Pharmaceutical GroupPhase 2
35
Stage I: HSK21542 0.5 μg/kg + Stage I: HSK21542 1 μg/kg + HSK21542 0.5 μg/kg + HSK21542 1 μg/kg + HSK21542 2 μg/kg + PlaceboHaisco Pharmaceutical GroupPhase 2
35
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
40
HTX-011 + Ibuprofen + Acetaminophen + Celecoxib + +/- Bupivacaine HCl + HTX-011Heron TherapeuticsPhase 3
30
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenHeron TherapeuticsApproved
33
HTX-011 + HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 2
25
Bupivacaine HClHeron TherapeuticsApproved
33
HTX-011 + PlaceboHeron TherapeuticsPhase 2
25
HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 3
30
Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionHeron TherapeuticsApproved
33
HTX-011 + Bupivacaine HCl + HTX-011 + HTX-011 + HTX-011Heron TherapeuticsPhase 2
17